Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse

Khalaud Naseeb Alhajry (1) , Zahra Mohammed Sukairi (2) , Hamidah Abdullah Lajami (2) , Safiah Anber Bin Ali Ibrahim (3) , Nawal Obaid Alanazi (4) , Eman Ali Alsafwani (5) , Ashwag Saad Hnif Albishi , Nada Naser Alomi , Zahrh Ahmed Ali Al-Hamadah , Anwar Mehdaf Akash Alrowaly (6)
(1) Al-Murooj Health Centre, Ministry Of Health, Saudi Arabia,
(2) Qatif Central Hospital , Ministry Of Health, Saudi Arabia,
(3) Department of Nursing Affairs in Community Health,Ministry Of Health, Saudi Arabia,
(4) School Health - Executive Administration for Medical Affairs in Community Health Excellence in Cluster1,Riyadh, Ministry of Health, Saudi Arabia,
(5) Model of Care - Executive Administration for Medical Affairs in Community Health Excellence Cluster 1, Riyadh,Ministry of Health, Saudi Arabia,
(6) Alyamamh Hospital,Ministry of Health, Saudi Arabia

Abstract

Background: Psychedelic-assisted therapy (PAT) is experiencing a resurgence, with expanding evidence proving its efficacy for treatment-resistant psychiatric-mental health conditions. Psychiatric-mental health nurses (PMHNs) are uniquely positioned to provide PAT due to their integrated care capabilities, yet their roles are poorly defined.


Aim: This review synthesizes PAT's clinical applications, mechanisms, and issues, focusing on PMHNs' preparation, dosing, and integration roles, while proposing training and policy guidelines to enhance their involvement.


Methods: A systematic search of peer-reviewed literature, clinical trials, meta-analyses, and nursing scholarship was conducted. The databases of PubMed, PsycINFO, and CINAHL were used to conduct searches for 2000-2025 studies related to the use of psilocybin, MDMA, and LSD. 


Results: PAT has robust effectiveness for depression, PTSD, substance use disorders, and end-of-life distress with effect sizes of 0.7-1.2. PMHNs enter safety and outcomes through trust building, monitoring, and integration, but only lead 5% of trials. Legal barriers, lack of funding, and inequities persist.


Conclusion: PMHNs are the key to equitable adoption of PAT, requiring greater training, research leadership, and policy leverage to achieve maximum benefit.

Full text article

Generated from XML file

References

Agin-Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponté, K. L., Guss, J., ... & Ross, S. (2020). Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of psychopharmacology, 34(2), 155-166. https://doi.org/10.1177/0269881119897615

Andersen, K. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021). Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies. Acta Psychiatrica Scandinavica, 143(2), 101-118. https://doi.org/10.1111/acps.13249

APNA. (2020). American Psychiatric Nurses Association annual conference proceedings. https://www.apna.org

Barnett, B. S., Siu, W. O., & Pope Jr, H. G. (2018). A survey of American psychiatrists' attitudes toward classic hallucinogens. The Journal of nervous and mental disease, 206(6), 476-480. DOI: 10.1097/NMD.0000000000000828

Beaussant, Y., Sanders, J., Sager, Z., Tulsky, J. A., Braun, I. M., Blinderman, C. D., ... & Byock, I. (2020). Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert clinicians' and investigators' perspectives. Journal of palliative medicine, 23(10), 1323-1334. https://doi.org/10.1089/jpm.2019.0603

Berg, L. (1994). Notes from a psychedelic research nurse. Newsletter of the Multidisciplinary Association for Psychedelics Studies, 5(1).

Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., ... & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA psychiatry, 79(10), 953-962. doi:10.1001/jamapsychiatry.2022.2096

Bowen, W. T., Soskin, R. A., & Chotlos, J. W. (1970). Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: a follow-up study. The Journal of nervous and mental disease, 150(2), 111-118.

Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology, 42(11), 2105-2113. https://doi.org/10.1038/npp.2017.84

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., ... & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853-4858. https://doi.org/10.1073/pnas.1518377113

Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant: a systematic review and meta‐analysis. Human Psychopharmacology: Clinical and Experimental, 30(3), 152-163. https://doi.org/10.1002/hup.2475

Dames, S., Watler, C., Kryskow, P., Allard, P., Gagnon, M., & Tsang, V. (2023). Psychedelic-assisted therapy training: Firsthand experience of non-ordinary states of consciousness in the development of competence. change, 16, 17.

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., ... & Griffiths, R. R. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry, 78(5), 481-489. doi:10.1001/jamapsychiatry.2020.3285

Denis-Lalonde, D., & Estefan, A. (2020). Emerging psychedelic-assisted therapies: Implications for nursing practice. Journal of Mental Health and Addiction Nursing, 4(1), e1-e13. https://doi.org/10.22374/jmhan.v4i1.40

Desrochers, S. (2024). Emerging needs and psychedelic-assisted therapy: stories of 2SGLBTQ+ experiences of psychedelic consciousness (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca.

Dishotsky, N. I., Loughman, W. D., Mogar, R. E., & Lipscomb, W. R. (1971). LSD and genetic damage: Is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic?. Science, 172(3982), 431-440. https://doi.org/10.1126/science.172.3982.431

Fallatah, A. R., Hawsawi, A. M. T., Makrami, R. A. H., Makrami, M. A. H., Jaber, S. A. H., Alanazi, K. S. sweet, … Al-Dosari, N. M. H. (2024). The Effect of Climate Change on Nursing: Climate Health Emergencies Preparedness Amidst Extreme Weather Conditions. Saudi Journal of Medicine and Public Health, *1*(1), 123–130. https://doi.org/10.64483/jmph-54

Garcia-Romeu, A., R. Griffiths, R., & W. Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current drug abuse reviews, 7(3), 157-164. https://doi.org/10.2174/1874473708666150107121331

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., ... & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology, 30(12), 1181-1197. https://doi.org/10.1177/0269881116675513

Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of psychopharmacology, 36(2), 151-158. https://doi.org/10.1177/02698811211073759

Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. Journal of psychopharmacology, 30(12), 1259-1267. https://doi.org/10.1177/0269881116677852

Hazazi, Y. O. (2025). Strengthening Postpartum Depression Screening and Treatment within Primary Healthcare Centers in Riyadh 1st Cluster. Saudi Journal of Medicine and Public Health, *2*(2), 105–113. https://doi.org/10.64483/jmph-56

Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of psychopharmacology, 22(6), 603-620. https://doi.org/10.1177/0269881108093587

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of psychopharmacology, 28(11), 983-992. https://doi.org/10.1177/0269881114548296

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & therapeutics, 197, 83-102. https://doi.org/10.1016/j.pharmthera.2018.11.010

Madkhali, A. M., Bouri, H. A., Alotaibi, F. O. E., ALMUTAIRI, A. M. M., Albalawi, T. suliman, Alotaibi, G. S., … Alotaibi, A. S. (2024). Potential Health Implications of Fifth Generation (5G) Wireless Communication Technology: A Review of Emerging Biological and Epidemiological Concerns. Saudi Journal of Medicine and Public Health, *1*(1), 94–105. https://doi.org/10.64483/jmph-53

Michaels, T. I., Purdon, J., Collins, A., & Williams, M. T. (2018). Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC psychiatry, 18(1), 1-14. https://doi.org/10.1186/s12888-018-1824-6

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., ... & Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature medicine, 27(6), 1025-1033. https://doi.org/10.1038/s41591-021-01336-3

Mitchell, J. M., Ot’alora G, M., van der Kolk, B., Shannon, S., Bogenschutz, M., Gelfand, Y., ... & Yazar-Klosinski, B. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473-2480. https://doi.org/10.1038/s41591-023-02565-4

Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., ... & Doblin, R. (2019). RETRACTED ARTICLE: MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236(9), 2735-2745. https://doi.org/10.1007/s00213-019-05249-5

Nasr, I. M., Al Ruweili, H. M. F., & alotaibi, H. moutlq M. (2025). The Significance of Routine Abdominal Ultrasound Before Bariatric Surgery. Saudi Journal of Medicine and Public Health, *2*(2), 147–158. https://doi.org/10.64483/jmph-68

Noorani, T., Garcia-Romeu, A., Swift, T. C., Griffiths, R. R., & Johnson, M. W. (2018). Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of psychopharmacology, 32(7), 756-769. https://doi.org/10.1177/0269881118780612

Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., ... & Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological medicine, 49(4), 655-663. doi:10.1017/S0033291718001356

Parley, K. A. Y. (1964). Supporting the patient. AJN The American Journal of Nursing, 64(2), 80-82.

Penn, A. D., Phelps, J., Rosa, W. E., & Watson, J. (2024). Psychedelic-assisted psychotherapy practices and human caring science: Toward a care-informed model of treatment. Journal of Humanistic Psychology, 64(4), 592-617. https://doi.org/10.1177/00221678211011013

Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., ... & Work Group on Biomarkers and Novel Treatments, a Division of the American Psychiatric Association Council of Research. (2020). Psychedelics and psychedelic-assisted psychotherapy. American Journal of Psychiatry, 177(5), 391-410. https://doi.org/10.1176/appi.ajp.2019.19010035

Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in pharmacology, 8, 974. https://doi.org/10.3389/fphar.2017.00974

Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry, 163(11), 1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905

Saud Faleh Alanazi. (2024). Comparative Evaluation of the Pharmacological Mechanisms, Clinical Indications, and Risk Management Strategies of Epidural Anesthesia in Surgical and Obstetric Interventions. Saudi Journal of Medicine and Public Health, *1*(1), 47–57. https://doi.org/10.64483/jmph-36

Sessa, B. (2020). The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. Aeon Books.

Spotswood, C. J. (2024). Psychedelics in psychiatry, the nursing influence, and the future of psychedelic therapies. Journal of the American Psychiatric Nurses Association, 30(5), 906-913. https://doi.org/10.1177/10783903231222930

Steenkamp, M. M., Litz, B. T., Hoge, C. W., & Marmar, C. R. (2015). Psychotherapy for military-related PTSD: A review of randomized clinical trials. Jama, 314(5), 489-500. doi:10.1001/jama.2015.8370

Strassman, R. (2000). DMT: The spirit molecule: A doctor's revolutionary research into the biology of near-death and mystical experiences. Simon and Schuster.

Utah Patients Coalition. (2023). Psychedelic therapy access: Lessons from Oregon and Colorado. https://www.utahpatients.org

Watson, J. (2013). Nursing: The philosophy and science of caring, revised edition. Caring in nursing classics: An essential resource, 243-264.

Weleff, J., Akiki, T. J., & Barnett, B. S. (2023). Bibliometric analysis of academic journal articles reporting results of psychedelic clinical studies. Journal of Psychoactive Drugs, 55(4), 434-444. https://doi.org/10.1080/02791072.2022.2133757

Wheeler, S. W., & Dyer, N. L. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice, 7(3), 279. https://psycnet.apa.org/doi/10.1037/cns0000237

WHO. (2022). Mental health atlas 2022. World Health Organization. https://www.who.int/publications/i/item/9789240036703

Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., ... & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481-486. https://doi.org/10.1038/nature17998

Authors

Khalaud Naseeb Alhajry
Kalhjri@moh.gov.sa (Primary Contact)
Zahra Mohammed Sukairi
Hamidah Abdullah Lajami
Safiah Anber Bin Ali Ibrahim
Nawal Obaid Alanazi
Eman Ali Alsafwani
Ashwag Saad Hnif Albishi
Nada Naser Alomi
Zahrh Ahmed Ali Al-Hamadah
Anwar Mehdaf Akash Alrowaly
Alhajry, K. N., Sukairi, Z. M., Lajami, H. A., Ibrahim, S. A. B. A., Alanazi, N. O., Alsafwani, E. A., … Alrowaly, A. M. A. (2024). Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse. Saudi Journal of Medicine and Public Health, 1(1), 400–409. https://doi.org/10.64483/jmph-116

Article Details

Similar Articles

<< < 2 3 4 5 6 > >> 

You may also start an advanced similarity search for this article.